ENDONOVO THERAPEUTICS, INC.

Stimcell Energetics Inc.STME · BiotechVancouver, Canada

69% matchPublic

StimCell Energetics Inc. is a biotechnology company focused on the research, development, and market introduction of both therapeutic and non-therapeutic solutions. These products are intended to benefit individuals in the United States who are managing conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and issues with kidney function. The company's primary product line is the eBalance system, which comprises two versions: the eBalance Pro System, designed for clinical application by healthcare practitioners, and the eBalance Home System, created for personal use to promote overall well-being and alleviate pain. Both systems are operated via the eBalance Console, a central control unit that offers three distinct pre-programmed microcurrent algorithms: one for general wellness, another for pain relief, and a 'dual' mode that combines both. Additionally, these eBalance products aim to provide temporary relief for discomfort in various body parts, including the shoulders, waist, back, neck, arms, and legs. Established in 2010, the company initially operated under the name Cell MedX Corp. before officially rebranding as StimCell Energetics Inc. in November 2024. Its corporate headquarters are located in Vancouver, Canada.

Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.

Sernova Biotherapeutics Inc.SEOVF · BiotechMississauga, Canada

65% matchPublic

Sernova Corp. is a Canadian firm, established in 1998 and headquartered in London, that specializes in advanced regenerative medicine therapeutics and is currently in its clinical development phase. The company's primary objective is to innovate and bring to market novel treatments, with a core focus on its unique "Cell Pouch" system. This sophisticated medical device is engineered to create a highly vascularized environment within the body, enabling the successful implantation and integration of therapeutic cells. Once integrated, these cells are designed to continuously release vital proteins or hormones, providing a long-term approach to managing debilitating chronic conditions like diabetes, hemophilia, and thyroid disease. Accompanying the Cell Pouch are related technologies that involve specialized therapeutic cells and methods to shield them from the body's immune response. Sernova actively collaborates with AgeX Therapeutics, Inc. to develop immune-protected therapeutic cells and maintains a research partnership with the University of Miami to further refine its Cell Pouch cell therapy platform.

Nobilis Therapeutics, Inc. is a Delaware C-corporation headquartered in Portland, Oregon, focused on the therapeutic uses of inert gas mixtures and portable delivery devices.

RetinalGenix Technologies Inc.RTGN · BiotechApollo Beach, United States

65% matchPublic

RetinalGenix Technologies Inc. is a company dedicated to research and development within the field of ophthalmology. Its core mission involves devising advanced technologies aimed at detecting, supervising, identifying, and treating a range of visual conditions, including those affecting the eyes and those that could lead to vision loss. Their product lineup features the RetinalGeniX Imaging System, an apparatus for broad-scale retinal imaging and screening that does not require pupil dilation, particularly useful for diabetic patients. Additionally, they offer the RetinalCam, a device designed for real-time retinal monitoring and imaging in a home setting, which includes an alert function for medical practitioners. The company was founded in 2017, with its principal offices located in Petaluma, California. RetinalGenix Technologies Inc. operates as a subsidiary of Sanovas Ophthalmology, LLC.

Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.